Press Release
Global Treatment for Syndromes of Dementia and Movement Disorders Market is Estimated to Reach $28.6 Billion by 2024, Says Variant Market Research
 Published Date:  Aug 2017  Publish By: Variant Market Research

Global Treatment for Syndromes of Dementia and Movement Disorders Market Report, published by Variant Market Research, forecast that the global market is expected to reach $28.6 Billion by 2024 from $14.5 Billion in 2016, growing at a CAGR of 8.9% from 2016 to 2024. By geography, Asia-Pacific and Europe are expected to grow at a CAGR of 9.9% and 9.1%, respectively, during the forecast period.

"Treatment for Syndromes of Dementia and Movement Disorders Market (By Type: Movement Disorders, Progressive Dementia, and Progressive Dementia with Neurological Abnormalities; By Geography: North America, Europe, Asia-Pacific and RoW) Global Scenario, Market Size, Outlook, Trend, and Forecast, 2015-2024"

To browse the complete report, visit at: https://www.variantmarketresearch.com/report-categories/pharmaceuticals/treatment-for-syndromes-of-dementia-and-movement-disorders-market

The factors supporting the growth of the market include rising geriatric population, increasing knowledge and accessibility towards various healthcare services such as homecare services and psychological services, growing investments in R&D, and increasing rate of neurodegenerative disorders. Though, lack of appropriate disorder management and long approval time for drugs and devices could limit the growth of the market. Additionally, untapped markets, especially in emerging economies and several awareness programs to improve the level of knowledge would provide growth prospects for the market in the forecast period 2016 – 2024.

Type and geography are the two major segments considered in the global treatment for syndromes of dementia and movement disorders market. By type, the segment is categorized into movement disorders (Parkinson’s disease, progressive supranuclear palsy, multiple system atrophy, hallervorden-spatz disease and others), progressive dementia (Alzheimer’s disease, Lewy body dementia, frontotemporal dementia/pick and others) and progressive dementia with neurological abnormality (Huntington’s disease, corticobasal ganglionic degeneration, amyotrophic lateral sclerosis(ALS)). Among which, progressive dementia is anticipated to dominate the market with highest revenue from 2015 to 2024.

By geography, the market has been bifurcated into North America, Europe, Asia-Pacific, and Rest of the World (RoW). North America accounted for the largest market share with 42.2% in 2016, driven by presence of large number of elderly population, increasing R&D investments, and unhealthy lifestyles, followed by Europe with 25.8%. In terms of growth, Asia-Pacific is expected to grow with fastest CAGR, owing to, presence of large population base, increasing knowledge, and expanding healthcare facilities.

Major players in the market include Valeant Pharmaceutical International, AstraZeneca GmbH, F. Hoffmann-La Roche, AG, Abbott Laboratories, Inc., Merck & Co., Inc., Sanofi S.A., Novartis AS, Bristol-Myers Squibb, Baxter International, Inc., and Pfizer, Inc., among others.

Contact Us:

John Dave,
Head - Sales 
Variant Market Research
649 Mission St, 5th Floor, San Francisco, CA 94105, United States.
Tel: +91-953-444-8373
Email: john.dave@variantmarketresearch.com 
Email: help@variantmarketresearch.com


GET MORE INFORMATION ABOUT THIS REPORT


Refresh Captcha

Chapter 1 Prefix
    1.1 Market Scope
    1.2 Report Description
    1.3 Research Methodology
          1.3.1 Primary Research
          1.3.2 Secondary Research
          1.3.3 In-house Data Modeling
Chapter 2 Executive Summary
Chapter 3 Market Outline
    3.1 Market Inclination, Trend, Outlook and Viewpoint
    3.2 Market Share Analysis: Company’s Competitive Scenario
    3.3 Market Dynamics
          3.3.1 Drivers
                   3.3.1.1 Impact Analysis
          3.3.2 Restraints
                   3.3.2.1 Impact Analysis
          3.3.3 Opportunities
Chapter 4 Treatment for Syndromes of Dementia and Movement Disorders Market by Type: Market Size and Forecast, 2015 – 2024
    4.1 Overview
    4.2 Movement Disorders
          4.2.1 Current Trend and Analysis
          4.2.2 Market Size and Forecast
          4.2.3 Parkinson’s Disease
          4.2.4 Progressive Supranuclear Palsy
          4.2.4 Multiple System Atrophy
          4.2.6 Hallervorden-Spatz Disease
          4.2.7 Others
    4.3 Progressive Dementia
          4.3.1 Current Trend and Analysis
          4.3.2 Market Size and Forecast
          4.3.3 Alzheimer’s Disease
          4.3.4 Lewy Body Dementia
          4.3.5 Frontotemporal Dementia/Pick
          4.3.6 Others
    4.4 Progressive Dementia with Neurological Abnormality
          4.4.1 Current Trend and Analysis
          4.4.2 Market Size and Forecast
          4.4.3 Huntington’s Disease
          4.4.4 Corticobasal Ganglionic Degeneration
          4.4.5 Amyotrophic Lateral Sclerosis(ALS)
Chapter 5 Treatment for Syndromes of Dementia and Movement Disorders Market by Geography: Market Size and Forecast, 2015 – 2024
    5.1 Overview
    5.2 North America
          5.2.1 Current Trend and Analysis
          5.2.2 Market Size and Forecast
          5.2.3 US
                   5.2.3.1 Market Size and Forecast
          5.2.4 Canada
                   5.2.4.1 Market Size and Forecast
          5.2.5 Mexico
                   5.2.5.1 Market Size and Forecast
    5.3 Europe
          5.3.1 Current Trend and Analysis
          5.3.2 Market Size and Forecast
          5.3.3 UK
                   5.3.3.1 Market Size and Forecast
          5.3.4 Germany
                   5.3.4.1 Market Size and Forecast
          5.3.5 France
                   5.3.5.1 Market Size and Forecast
          5.3.6 Italy
                   5.3.6.1 Market Size and Forecast
          5.3.7 Spain
                   5.3.7.1 Market Size and Forecast
          5.3.8 Others
                   5.3.8.1 Market Size and Forecast
    5.4 Asia-Pacific
          5.4.1 Current Trend and Analysis
          5.4.2 Market Size and Forecast
          5.4.3 Japan
                   5.4.3.1 Market Size and Forecast
          5.4.4 China
                   5.4.4.1 Market Size and Forecast
          5.4.5 India
                   5.4.5.1 Market Size and Forecast
          5.4.6 Others
                   5.4.6.1 Market Size and Forecast
    5.5 RoW
          5.5.1 Current Trend and Analysis
          5.5.2 Market Size and Forecast
          5.5.3 Middle East
                   5.5.3.1 Market Size and Forecast
          5.5.4 South America
                   5.5.4.1 Market Size and Forecast
          5.5.5 Africa
                   5.5.5.1 Market Size and Forecast
Chapter 6 Company Profiles
    6.1 Valeant Pharmaceutical International
    6.2 AstraZeneca GmbH
    6.3 F. Hoffmann-La Roche, AG
    6.4 Abbott Laboratories, Inc.
    6.5 Merck & Co., Inc.
    6.6 Sanofi S.A.
    6.7 Novartis AG
    6.8 Bristol-Myers Squibb
    6.9 Baxter International, Inc.
    6.10 Pfizer, Inc.

GET MORE INFORMATION ABOUT THIS REPORT


Refresh Captcha

Please fill the form below and our research expert will get in touch with you.


Refresh Captcha

Please fill the form below and our research expert will get in touch with you.


Refresh Captcha